Archford Capital Strategies’s Regeneron Pharmaceuticals REGN Stock Holding History

Archford Capital Strategies’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$650K	Buy	1,043 +5	+0.5%	+$3.4K	0.07%	214
2026 Q1	$802K	Buy	+1,038	New	+$795K	0.09%	187
2021 Q4	–	Sell	-971	Closed	-$588K	–	311
2021 Q3	$588K	Buy	971 +16	+2%	+$9.93K	0.14%	172
2021 Q2	$533K	Buy	955 +63	+7%	+$31.9K	0.13%	170
2021 Q1	$441K	Buy	892 +266	+42%	+$130K	0.12%	187
2020 Q4	$312K	Buy	626 +194	+45%	+$105K	0.07%	230
2020 Q3	$242K	Sell	432 -123	-22%	-$74.6K	0.06%	232
2020 Q2	$346K	Buy	555 +72	+15%	+$40.9K	0.1%	191
2020 Q1	$236K	Buy	+483	New	+$199K	0.09%	198

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Archford Capital Strategies's REGN Position: Q2 2026 in Review

Archford Capital Strategies increased its Regeneron Pharmaceuticals (REGN) stake by 0.48% in Q2 2026, buying an estimated $3.4K and bringing the position to 1,043 shares worth $650K. The position accounts for 0.07% of the portfolio, ranked #214.

Archford Capital Strategies first reported a position in REGN in Q1 2020 and has held it in 9 quarters since. The position peaked at $802K in Q1 2026. 374 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Archford Capital Strategies held 1,043 shares of Regeneron Pharmaceuticals worth $650K as of Q2 2026.
Archford Capital Strategies bought 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.4K.
Regeneron Pharmaceuticals made up 0.07% of Archford Capital Strategies's portfolio in Q2 2026, its #214 holding.
Archford Capital Strategies first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 9 quarters since.
Archford Capital Strategies's Regeneron Pharmaceuticals position peaked at $802K in Q1 2026.
374 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Archford Capital Strategies's 13F filing for Q2 2026, filed 17 Jul 2026.